|
Top Stories Wednesday, June 29, 2016 Merck will pay $200 million upfront to Moderna, which the company will use to lead all R&D efforts through proof of concept and to build out a suburban Boston manufacturing facility. The program will focus on several types of cancer and include combinations with Merck’s Keytruda (pembrolizumab). Wednesday, June 29, 2016 Galena Biopharma fell more than 80% in premarket trading on news that an Independent Data Monitoring Committee stopped a Phase III trial of its NeuVax in early stage breast cancer for futility. Wednesday, June 29, 2016 Oncology drug czar Dr. Richard Pazdur--who earlier this month despaired at biopharma’s “me-too” approach to cancer development--has been named as the interim leader of a new Oncology Center of Excellence that will be run out of the FDA. Tuesday, June 28, 2016 Gilead has seen its new combo of sofosbuvir and velpatasvir gain FDA approval as the company now offers a new cocktail that can treat all 6 types of hep C. Wednesday, June 29, 2016 Pfizer has posted positive data from two more trials for its new experimental anti-cholesterol drug bococizumab as the three-way dual for the PCSK9 inhibitor market heats up. Wednesday, June 29, 2016 Herbert Stadler’s Ellersbrook has invested in Evotec’s in-house NASH drug discovery program. The deal sees Ellersbrook and Evotec agree to jointly bankroll the advance of NASH programs, with a view to spinning them off into an independent startup or partnering them with a biopharma company down the line.
| | | Lipocine has seen its shares tank as the FDA refused to approve its testosterone drug, saying there are problems with the treatment’s label and dosing algorithm. Release Cambridge, MA-based Cyteir Therapeutics has been given a $2 million, 2-year grant from the NCI to support preclinical development of its RAD51 modulator for the treatment of cancers. Statement Agilis Biotherapeutics has been given an Orphan Drug Designation by the FDA for the treatment of Aromatic L-amino Acid Decarboxylase Deficiency. Release New York’s BeyondSpring has launched a Phase III NSCLC trial for its candidate plinabulin in China. Statement | |
|
Resources Sponsored by: SDC
Interested in intended use validation of SaaS-based EDC systems? Prefer to discuss rescue study strategies and considerations? How about understanding statistical power for non-statisticians? Vote for your favorite webinar topic to be presented by SDC at DIA on June 28, 2016, 12pm EDT. Cast Your Vote Here to receive your exclusive event invitation and a recording of the webinar after the event. Sponsored by: Covance
Al Blunt, MD, Executive Medical Director, Oncology at Covance discusses how the lessons learned from the past decade of developing targeted therapies are relevant to the future development of cancer immunotherapy. Download today! Sponsored by: Veeva Systems
Gartner research on short- and long-term strategies for IDMP compliance.
| 
